Olema Pharmaceuticals, Inc. (OLMA) NASDAQ

Currency In USD

Olema Pharmaceuticals, Inc.

Address

512 2nd Street

San Francisco, CA 94107

United States of America (the)

Phone

650 243 5555

Website

https://www.olema.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

November 19, 2020

Key Executives

Name	Title	Pay	Year Born
Sean Bohen	President, CEO, Interim Principal Financial Officer & Director	1.18M	1967
David C. Myles	Chief Scientific Officer	200,000	1963
Shawnte Mitchell	Chief Legal Officer & Corporate Secretary	664,750	1978
Naseem Zojwalla	Chief Medical Officer	777,970	1973
Shane William Charles Kovacs	Consultant	902,735	1974
Julie Dexter	Senior Vice President & Head of People	0	N/A
Meghna Chowdary	Senior Vice President of Commercial Strategy & Operations	0	N/A
Sasha Austin	Vice President of Finance & Controller	0	N/A
Angelos Dovletoglou	Senior Vice President of CMC & Supply Chain	0	N/A
Kamesh Kuchimanchi	Senior Vice President of Regulatory Affairs & Quality Assurance	0	N/A
Mark Shilkrut	Senior Vice President of Clinical Development	0	N/A
Richard Hernandez	Senior Vice President of Clinical Development Operations	0	N/A
Courtney O'Konek	Vice President of Corporate Communications	0	N/A

Description

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.